Results per Page:
New horizons in infectious disease treatment and prevention in immunocompromised patients
The 5th Symposium on Infectious Disease in the Immunocompromised Host emphasized new opportunities, next generation
Donor factors influence success of fecal microbiota transplant
From the Rashidi Group, Pathogen Associated Malignancies Program of the Cancer Consortium and Clinical Research Division
Decisions, decisions: factors that impact HCT outcomes in AML
From the Walter Group, Translational Sciences and Therapeutics Division
Could fecal microbiota transplantation help patients heal after stem cell transplantation?
Phase 2 clinical trial shows a safe dose from a specific donor helped with gut microbiome recovery in people with cancer
Mutations remain one-in-a-million after HCT
From the Storb Group, Clinical Research Division
A charming model: new tool evaluates risk of transplant for older patients
Seven values are evaluated to predict outcomes
Improving blood stem cell transplantation outcomes by treating donors
From the Mielcarek Group, Clinical Research Division
Something new and something old synergize to limit multiple myeloma relapse
From the Hill Lab, Translational Science and Therapeutics Division
Patients navigate cancer during COVID-19 pandemic
Scary waiting rooms, delayed scans and ‘virtual’ care: patients and providers try to dodge the collateral damage of coronavirus
Coronavirus: what cancer patients need to know
Advice for cancer patients, survivors and caregivers on who’s most at risk for COVID-19 and what you can do to stay healthy
Dr. Steve Pergam receives Dr. Ali Al-Johani Award
An expert in infection prevention who is also a 'passionate patient care advocate and an outstanding physician'